Literature DB >> 30026231

Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.

Fernando Salgado-Polo1, Alex Fish1, Minos-Timotheos Matsoukas1,2, Tatjana Heidebrecht1, Willem-Jan Keune1, Anastassis Perrakis3.   

Abstract

Autotaxin (ATX) is a secreted glycoprotein and the only member of the ectonucleotide pyrophosphatase/phosphodiesterase family that converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). LPA controls key responses, such as cell migration, proliferation, and survival, implicating ATX-LPA signaling in various (patho)physiological processes and establishing it as a drug target. ATX structural and functional studies have revealed an orthosteric and an allosteric site, called the "pocket" and the "tunnel," respectively. However, the mechanisms in allosteric modulation of ATX's activity as a lysophospholipase D are unclear. Here, using the physiological LPC substrate, a new fluorescent substrate, and diverse ATX inhibitors, we revisited the kinetics and allosteric regulation of the ATX catalytic cycle, dissecting the different steps and pathways leading to LPC hydrolysis. We found that ATX activity is stimulated by LPA and that LPA activates ATX lysophospholipase D activity by binding to the ATX tunnel. A consolidation of all experimental kinetics data yielded a comprehensive catalytic model supported by molecular modeling simulations and suggested a positive feedback mechanism that is regulated by the abundance of the LPA products activating hydrolysis of different LPC species. Our results complement and extend the current understanding of ATX hydrolysis in light of the allosteric regulation by ATX-produced LPA species and have implications for the design and application of both orthosteric and allosteric ATX inhibitors.
© 2018 Salgado-Polo et al.

Entities:  

Keywords:  ATX; ENPP2; LPA; allosteric regulation; allostery; autotaxin; enzyme kinetics; lysophospholipid; molecular dynamics; phosphodiesterases; phospholipase; phospholipid turnover

Mesh:

Substances:

Year:  2018        PMID: 30026231      PMCID: PMC6139564          DOI: 10.1074/jbc.RA118.004450

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Design and synthesis of an enzyme-cleavable sensor molecule for phosphodiesterase activity based on fluorescence resonance energy transfer.

Authors:  Hideo Takakusa; Kazuya Kikuchi; Yasuteru Urano; Shigeru Sakamoto; Kentaro Yamaguchi; Tetsuo Nagano
Journal:  J Am Chem Soc       Date:  2002-02-27       Impact factor: 15.419

2.  Discovery of potent inhibitors of the lysophospholipase autotaxin.

Authors:  Pritom Shah; Anne Cheasty; Caroline Foxton; Tony Raynham; Muddasar Farooq; Irene Farre Gutierrez; Aurore Lejeune; Michelle Pritchard; Andrew Turnbull; Leon Pang; Paul Owen; Susan Boyd; Alexandra Stowell; Allan Jordan; Niall M Hamilton; James R Hitchin; Martin Stockley; Ellen MacDonald; Mar Jimenez Quesada; Elisabeth Trivier; Jana Skeete; Huib Ovaa; Wouter H Moolenaar; Hamish Ryder
Journal:  Bioorg Med Chem Lett       Date:  2016-10-14       Impact factor: 2.823

3.  Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.

Authors:  Laurens A van Meeteren; Paula Ruurs; Evangelos Christodoulou; James W Goding; Hideo Takakusa; Kazuya Kikuchi; Anastassis Perrakis; Tetsuo Nagano; Wouter H Moolenaar
Journal:  J Biol Chem       Date:  2005-03-15       Impact factor: 5.157

4.  Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.

Authors:  Lauren P Saunders; Wenxiang Cao; William C Chang; Ronald A Albright; Demetrios T Braddock; Enrique M De La Cruz
Journal:  J Biol Chem       Date:  2011-06-30       Impact factor: 5.157

5.  Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators.

Authors:  Willem-Jan Keune; Frances Potjewyd; Tatjana Heidebrecht; Fernando Salgado-Polo; Simon J F Macdonald; Lakshman Chelvarajan; Ahmed Abdel Latif; Sony Soman; Andrew J Morris; Allan J B Watson; Craig Jamieson; Anastassis Perrakis
Journal:  J Med Chem       Date:  2017-02-16       Impact factor: 7.446

6.  Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity.

Authors:  Colin G Ferguson; Cleve S Bigman; Robyn D Richardson; Laurens A van Meeteren; Wouter H Moolenaar; Glenn D Prestwich
Journal:  Org Lett       Date:  2006-05-11       Impact factor: 6.005

7.  Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D.

Authors:  Silvia Jansen; Cristiana Stefan; John W M Creemers; Etienne Waelkens; Aleyde Van Eynde; Willy Stalmans; Mathieu Bollen
Journal:  J Cell Sci       Date:  2005-06-28       Impact factor: 5.285

8.  The polybasic insertion in autotaxin α confers specific binding to heparin and cell surface heparan sulfate proteoglycans.

Authors:  Anna J S Houben; Xander M R van Wijk; Laurens A van Meeteren; Leonie van Zeijl; Els M A van de Westerlo; Jens Hausmann; Alexander Fish; Anastassis Perrakis; Toin H van Kuppevelt; Wouter H Moolenaar
Journal:  J Biol Chem       Date:  2012-11-13       Impact factor: 5.157

Review 9.  Autotaxin: structure-function and signaling.

Authors:  Anastassis Perrakis; Wouter H Moolenaar
Journal:  J Lipid Res       Date:  2014-02-18       Impact factor: 5.922

10.  Improved side-chain torsion potentials for the Amber ff99SB protein force field.

Authors:  Kresten Lindorff-Larsen; Stefano Piana; Kim Palmo; Paul Maragakis; John L Klepeis; Ron O Dror; David E Shaw
Journal:  Proteins       Date:  2010-06
View more
  7 in total

1.  Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells.

Authors:  Elisa Matas-Rico; Elselien Frijlink; Irene van der Haar Àvila; Apostolos Menegakis; Maaike van Zon; Andrew J Morris; Jan Koster; Fernando Salgado-Polo; Sander de Kivit; Telma Lança; Antonio Mazzocca; Zoë Johnson; John Haanen; Ton N Schumacher; Anastassis Perrakis; Inge Verbrugge; Joost H van den Berg; Jannie Borst; Wouter H Moolenaar
Journal:  Cell Rep       Date:  2021-11-16       Impact factor: 9.423

2.  2-Carba-lysophosphatidic acid is a novel β-lysophosphatidic acid analogue with high potential for lysophosphatidic acid receptor activation and autotaxin inhibition.

Authors:  Keiko Fukasawa; Mari Gotoh; Akiharu Uwamizu; Takatsugu Hirokawa; Masaki Ishikawa; Yoshibumi Shimizu; Shinji Yamamoto; Kensuke Iwasa; Keisuke Yoshikawa; Junken Aoki; Kimiko Murakami-Murofushi
Journal:  Sci Rep       Date:  2021-08-30       Impact factor: 4.379

3.  Phospholipase A1 Member A Activates Fibroblast-like Synoviocytes through the Autotaxin-Lysophosphatidic Acid Receptor Axis.

Authors:  Yang Zhao; Stephan Hasse; Myriam Vaillancourt; Chenqi Zhao; Lynn Davis; Eric Boilard; Paul Fortin; John Di Battista; Patrice E Poubelle; Sylvain G Bourgoin
Journal:  Int J Mol Sci       Date:  2021-11-24       Impact factor: 5.923

4.  Structure-Based Design of a Novel Class of Autotaxin Inhibitors Based on Endogenous Allosteric Modulators.

Authors:  Jennifer M Clark; Fernando Salgado-Polo; Simon J F Macdonald; Tim N Barrett; Anastassis Perrakis; Craig Jamieson
Journal:  J Med Chem       Date:  2022-04-20       Impact factor: 8.039

5.  A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis.

Authors:  Anastassis Perrakis; Ruchi Bansal; Richell Booijink; Fernando Salgado-Polo; Craig Jamieson
Journal:  EMBO Mol Med       Date:  2022-07-14       Impact factor: 14.260

Review 6.  The Structural Binding Mode of the Four Autotaxin Inhibitor Types that Differentially Affect Catalytic and Non-Catalytic Functions.

Authors:  Fernando Salgado-Polo; Anastassis Perrakis
Journal:  Cancers (Basel)       Date:  2019-10-16       Impact factor: 6.639

7.  Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.

Authors:  Christiana Magkrioti; Eleanna Kaffe; Elli-Anna Stylianaki; Camelia Sidahmet; Georgia Melagraki; Antreas Afantitis; Alexios N Matralis; Vassilis Aidinis
Journal:  Int J Mol Sci       Date:  2020-09-23       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.